Gilla Phd Kaplan Net Worth

The estimated Net Worth of Gilla Phd Kaplan is at least $29.1 Million dollars as of 18 May 2018. Gilla Kaplan owns over 27,750 units of Celgene stock worth over $11,235,427 and over the last 16 years Gilla sold CELG stock worth over $17,818,019.

Gilla Kaplan CELG stock SEC Form 4 insider trading

Gilla has made over 88 trades of the Celgene stock since 2004, according to the Form 4 filled with the SEC. Most recently Gilla exercised 27,750 units of CELG stock worth $832,778 on 18 May 2018.

The largest trade Gilla’s ever made was exercising 123,996 units of Celgene stock on 30 October 2006 worth over $332,309. On average, Gilla trades about 11,009 units every 38 days since 2003. As of 18 May 2018 Gilla still owns at least 104,051 units of Celgene stock.

You can see the complete history of Gilla Kaplan stock trades at the bottom of the page.

What’s Gilla Kaplan’s mailing address?

Gilla’s mailing address filed with the SEC is C/O CELGENE CORPORATION, , WARREN, NJ, 11050.

Insider trading at Celgene

Over the last 16 years, insiders at Celgene have traded over $348,919,594 worth of Celgene stock and bought 171,908 units worth $10,354,899 . The most active insider traders include Sol J Barer, Robert J Hugin, and John W Jackson. On average, Celgene executives and independent directors trade stock every 13 days with the average trade being worth of $5,423,484. The most recent stock trade was executed by Jonathan Biller on 31 October 2019, trading 3,125 units of CELG stock currently worth $336,531.

What does Celgene do?

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

What does Celgene’s logo look like?

Complete history of Gilla Kaplan stock trades at Celgene

Celgene executives and stock owners

Celgene executives and other stock owners filed with the SEC include:

Mark Alles, Chairman of the Board, Chief Executive Officer
Peter Kellogg, Executive Vice President and Chief Corporate Strategy Officer
Rupert Vessey, President – Research and Early Development
Michael Casey, Lead Independent Director
James Loughlin, Independent Director
Ernest Mario, Independent Director
Julia Haller, Director
Carrie Cox, Independent Director
Michael Bonney, Independent Director
Richard Barker, Independent Director
Michael Friedman, Independent Director
John Weiland, Independent Director
Patricia Hemingway Hall, Independent Director
Hans Bishop, Director
Jonathan Biller, Executive Vice President, General Counsel
Alise Reicin, President – Global Clinical Development
Terrie Curran, President, Global Inflammation & Immunology Franchise
David Elkins, Chief Financial Officer, Executive Vice President
Michael F. Pehl, See remarks
Gerald Masoudi, Executive Vice President
Gilla Phd Kaplan, Director
Scott Andrew Smith, See Remarks
Robert J Hugin, Chief Financial Officer
Nadim Ahmed, PRES., HEMATOLOGY AND ONCOLOGY
Lawrence V Stein, See Remarks
Rodman L Drake, Chief Operating Officer
Thomas O Daniel, see remarks
Hoek Andre Van, Controller and CAO
Walter L Robb, Director
Graham Burton, See Remarks
David W Gryska, Chief Financial Officer
Aart Brouwer, See Remarks
Sol J Barer, Chief Operating Officer
Richard C E Morgan, Director
Arthur H Jr Hayes, Director
Thomas M Moriarty, see remarks
Jacqualyn A Fouse, Chief Financial Officer
Perry A Karsen, see remarks
Jack L Bowman, Director
Frank T Cary, Director
John W Jackson, Chief Executive Officer

Gilla Phd Kaplan Net Worth